Home » Stocks » MRKR

Marker Therapeutics, Inc. (MRKR)

Stock Price: $2.27 USD -0.02 (-0.87%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
Market Cap 109.02M
Revenue (ttm) 679,979
Net Income (ttm) -25.28M
Shares Out 46.87M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $2.27
Previous Close $2.29
Change ($) -0.02
Change (%) -0.87%
Day's Open 2.28
Day's Range 2.02 - 2.34
Day's Volume 458,317
52-Week Range 1.32 - 3.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 month ago

HOUSTON, Jan. 13, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunot...

Benzinga - 2 months ago

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann...

Other stocks mentioned: VVOS, THC, CYTH
PRNewsWire - 2 months ago

HOUSTON, Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunoth...

Seeking Alpha - 3 months ago

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

HOUSTON, Nov. 9, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunoth...

PRNewsWire - 5 months ago

HOUSTON, Sept. 17, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

PRNewsWire - 6 months ago

HOUSTON, Aug. 10, 2020 /PRNewswire/ -- Marker Therapeutics, Inc.

PRNewsWire - 8 months ago

HOUSTON, June 30, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immuno...

PRNewsWire - 8 months ago

HOUSTON, June 23, 2020 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunot...

Seeking Alpha - 9 months ago

Marker Therapeutics, Inc. (MRKR) CEO Peter Hoang on Q1 2020 Results - Earnings Call Transcript

Investopedia - 10 months ago

Even in turbulent times, technical analysis helps pinpoint penny stocks that may be oversold and due for a positive trend reversal.

Other stocks mentioned: BW, CTEK, SONG, WBT
Market Watch - 10 months ago

The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics Inc.

Other stocks mentioned: TRUMY
Seeking Alpha - 1 year ago

Marker Therapeutics' (MRKR) CEO Peter Hoang on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Marker reports positive positive preliminary results in a phase 1/2 study using MultiTTA to treat patients with pancreatic cancer.

Seeking Alpha - 1 year ago

Marker Therapeutics' MultiTAA cell therapy has many advantages over other currently available therapies like CAR-T and TCR; most notable was the observation of epitope spreading which was an u...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor Marker Therapeutics.

Zacks Investment Research - 1 year ago

MARKER THERAPEUTICS, INC. (MRKR) delivered earnings and revenue surprises of 7.69% and -100.00%, respectively, for the quarter ended March 2019.

The Motley Fool - 1 year ago

An abstract detailing one of the company's clinical programs was rejected from an important industry meeting.

About MRKR

Marker Therapeutics, a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of ly... [Read more...]

Industry
Biotechnology
CEO
Peter Hoang
Employees
28
Stock Exchange
NASDAQ
Ticker Symbol
MRKR
Full Company Profile

Financial Performance

In 2019, MRKR's revenue was $213,194, an increase of 3.50% compared to the previous year's $205,994. Losses were -$21.43 million, -85.52% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for MRKR stock is "Buy." The 12-month stock price forecast is 7.00, which is an increase of 208.37% from the latest price.

Price Target
$7.00
(208.37% upside)
Analyst Consensus: Buy